2.2k
why does nobody talk about MASH
why does nobody talk about MASH, and I want the answer with the reasoning attached rather than just the conclusion. What this compound is actually being developed for,…
u/julia_mensa
Contributes reviews on supplier material. Based in Poznań.
member · joined 12 Mar 2025
2,363post karma
1,412comment karma
1submissions
16comments
comment on [Paper] survodutide MASH data is the most interesting hepatic readout in the class in c/survodutide · 32 points · 2 days ago
Sent a vial to Janoshik because there was nothing on file. 99.3% against a claimed 99.0%. First entry for this compound in my own log.
comment on glucagon co-agonism has its own safety story, stop generalising from tirz in c/survodutide · -4 points · 3 days ago
fibrosis improvement without worsening steatohepatitis is the phrase to learn
comment on glucagon co-agonism has its own safety story, stop generalising from tirz in c/survodutide · 2 points · 3 days ago
Careful with the mechanism claim. Glucagon agonism is plausible as an explanation and it has not been isolated as the operative one.
comment on [Trial Data] phase 2 biopsy endpoints, and what "resolution" means in c/survodutide · 110 points · 6 days ago
Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.
comment on is it normal to get constipation at week 7 in c/survodutide · 51 points · 1 months ago
the weight numbers are secondary to what this is being developed for
comment on is it normal to get constipation at week 7 in c/survodutide · -7 points · 1 months ago
Went slowly because everything published describes a deliberate escalation. That is the extent of what I will say about it.
comment on [Lab] GGPeps survo — VendorInvestigate came back 97.9% against a claimed 97.0% in c/survodutide · 7 points · 1 months ago
Not convinced. Imaging-based fat fraction is not the same as a histological response and the paper is explicit about that.
comment on why does nobody talk about dual agonist in c/survodutide · 6 points · 2 months ago
Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.
comment on [Question] how do you actually verify MASH in c/survodutide · 112 points · 4 months ago
this board is small because the compound is early
comment on small win: hepatic fat stopped being a problem at week 91 in c/survodutide · 22 points · 9 months ago
Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis wit
Disagreeing with this bit: that number comes from a different programme with a different population.
comment on [Discussion] MASH is doing more work than we give it credit for in c/survodutide · 36 points · 11 months ago
It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is oriented towards liver disease.
comment on small win: MASH stopped being a problem at week 43 in c/survodutide · 29 points · 1 year ago
Sent a vial to PeptideMeter because there was nothing on file. 99.3% against a claimed 99.0%. First entry for this compound in my own log.
comment on why does nobody talk about MASH in c/survodutide · 1 points · 2 years ago
fibrosis improvement without worsening steatohepatitis is the phrase to learn
comment on why does nobody talk about MASH in c/survodutide · 1 points · 2 years ago
phase 2 in liver disease is a different evidence question from weight
comment on why does nobody talk about MASH in c/survodutide · -25 points · 2 years ago
Sent a vial to Janoshik because there was nothing on file. 99.5% against a claimed 99.0%. First entry for this compound in my own log.
comment on [Lab] 8th independent test on JEEP — 97.2% on a claimed 97.0%, and the trend is the interesting part in c/survodutide · 36 points · 2 years ago
Phase 2 in a biopsy-confirmed population is a demanding design: recruitment is slow, the population is specific, and the results do not generalise to people who have not been characterised that way.